News and Press Releases
Research Cystic Fibrosis Foundation Strikes First-of-Its-Kind Deal With Pioneering Medicines, a Flagship Pioneering Initiative

Foundation to fund up to $110 million for collaboration to accelerate the development of genetic therapies for CF

Nov. 3, 2021 | 4 min read
Our Research Approach | Patient Registry | Research CF Foundation Launches Lung Transplant Biorepository and Patient Registry

The Cystic Fibrosis Lung Transplant Consortium Biorepository and Patient Registry, in collaboration with Cleveland Clinic, will provide critical clinical data and samples to support future research investigating complications of lung transplant.

Aug. 12, 2021 | 4 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Funds Three New Research Awards to Advance its Path to a Cure Initiative

New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations

May 27, 2021 | 5 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Invests Up to $8.4M in SpliSense for the Development of Potential Rare Mutation Therapy

Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations.

May 13, 2021 | 4 min read
Research Molecular Analysis Identifies Key Differences in Lungs of People With Cystic Fibrosis

Researchers' catalog of airway cell types could reveal targets for future genetic therapies

May 6, 2021 | 6 min read
Research | Drug Pipeline | Medications FDA Accepts Vertex Application for Expansion of Trikafta to Include Children ages 6-11

Today, Vertex Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted its application to expand Trikafta® (elexacaftor/tezacaftor/ivacaftor) to include children ages 6-11 years old with cystic fibrosis who have at least one F508del or a mutation in the CFTR gene that is responsive based on in vitro data. The FDA has granted priority review of the application and has indicated that it will make a decision by June 8, 2021. 

Jan. 26, 2021 | 2 min read